Abstract 1950
Background
Leukemia Inhibitory Factor (LIF) is a pleiotropic cytokine, highly expressed in a subset of tumors and correlates with poor prognosis. LIF is hypothesized to contribute to tumor microenvironment (TME) immunosuppression and regulation of cancer initiating cells. MSC-1 is a first-in-class humanized IgG1 monoclonal antibody that potently and selectively inhibits LIF. MSC-1 decreased tumor growth in mouse tumor models and generated durable regressions when combined with anti-PD-1.
Methods
Eligible pts had advanced relapsed/refractory solid tumors (regardless of pretreatment LIF tumor levels). The study employed an accelerated 3 + 3 escalation design to explore safety, dose-limiting toxicities (DLTs), preliminary efficacy, and define a recommended phase II dose (RP2D). Pts received treatment with MSC-1 intravenously (75mg-1500 mg) once every 3-weeks until disease progression. The three highest dose cohorts were expanded to further assess safety, PK, LIF peripheral target engagement, and to assess immuno-regulatory tumor activity in paired pre- and on treatment tumor tissue.
Results
Dose escalation enrollment was completed on March 6, 2019 with 41 pts (14 in dose escalation; 27 in expanded cohorts). There were no DLTs. As of April 26, 2019, there were 38 AEs (30 grade (Gr) 1,7 Gr 2, and 1 Gr 3), reported as possibly related to MSC-1 (fatigue in 10 pts and nausea in 4 pts were the most common). Overall PK profile was linear with estimated terminal half-life of ∼17 days and a benign anti-drug antibody profile. There was evidence of durable peripheral LIF saturation at higher doses or after multiple doses. Stable disease (≥ 16 weeks) was noted in 7 pts. Comparison of paired pretreatment and on treatment biopsies in the 1125mg expanded cohort, showed at least one mechanism-based change in all 4 evaluable patients, and in the two patients continuing therapy beyond 16 weeks, evidence of reversal of TME immunosuppression through infiltration of CD8 T cells and changes in macrophage populations.
Conclusions
MSC-1 holds promise as an anti-cancer therapy and should be readily combinable with other agents. Updated safety, efficacy, PK, LIF stabilization analyses, and paired tumor biopsy data will be presented.
Clinical trial identification
NCT03490669.
Editorial acknowledgement
Legal entity responsible for the study
Northern Biologics Inc.
Funding
Northern Biologics, Inc.
Disclosure
E. Borazanci: Speaker Bureau / Expert testimony: Ipsen; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Fujifilm; Advisory / Consultancy: Concept; Research grant / Funding (institution): Northern Biologics; Research grant / Funding (institution): Minneamrita; Research grant / Funding (institution): Fujifilm; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Bioline; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Ambry; Research grant / Funding (institution): Mabvax. A. Schram: Research grant / Funding (institution): Northern Biologics. I. Brana: Research grant / Funding (institution): Northern Biologics; Advisory / Consultancy, Research grant / Funding (self): Orion Pharmac; Speaker Bureau / Expert testimony, Research grant / Funding (self): BMS; Speaker Bureau / Expert testimony, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck Serono; Research grant / Funding (self): Celgene; Research grant / Funding (self): Gliknik; Research grant / Funding (self): GSK; Research grant / Funding (self): Jannsen; Research grant / Funding (self): Kura; Research grant / Funding (self): MSD; Research grant / Funding (self): Novartis; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche. M. Vieito Villar: Research grant / Funding (institution): Northern Biologics. E. Garralda: Research grant / Funding (institution): Northern Biologics; Advisory / Consultancy, Research grant / Funding (self): Roche Genentech Inc; Advisory / Consultancy: Ellipses Pharma; Advisory / Consultancy: Neomed Therapeutics1 Inc; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Janssen Global Services; Speaker Bureau / Expert testimony: BMS; Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Glycotope ; Research grant / Funding (self), Travel / Accommodation / Expenses: Menarini; Research grant / Funding (self): Novartis; Leadership role: ESMO; Research grant / Funding (self): Principia Biopharma Inc; Research grant / Funding (self): Lilly, S.A ; Research grant / Funding (self): Loxo Oncology Inc ; Research grant / Funding (self): Symphogen A/S ; Research grant / Funding (self): Incyte; Research grant / Funding (self): Pharma Mar; Research grant / Funding (self): MacroGenics; Research grant / Funding (self): Kura Oncology,Glycotope, Pierre Fabre, Blueprint Medicines , Beigene, Sierra Oncology, Genmab. A. Spreafico: Research grant / Funding (institution): Northern Biologics. M. Oliva: Research grant / Funding (institution): Northern Biologics. N. Lakhani: Research grant / Funding (institution): ALX Oncology; Research grant / Funding (institution): Forty Seven Inc; Research grant / Funding (institution): INhibRx; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): MacroGenics; Research grant / Funding (institution): Arqule; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Livzon; Research grant / Funding (institution): Ascentage; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Northern Biologics; Research grant / Funding (institution): Apexian; Research grant / Funding (institution): Asana Biosciences; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Formation Biologics/Forbius; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Constellation Pharma,; Research grant / Funding (institution): TaiRx, CytomX, Coordination Pharma, Symphogen, Cerulean, Jounce Therapeutics. R. Wasserman: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Northern Biologics. K. Hoffman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Northern Biologics. R. Hallett: Shareholder / Stockholder / Stock options, Full / Part-time employment: Northern Biologics. J. Anido: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Northern Biologics. P. Giblin: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Northern Biologics. N. Pandya: Shareholder / Stockholder / Stock options: Northern Biologics. A. Kelly: Advisory / Consultancy: Northern Biologics. J. Seoane: Advisory / Consultancy, Research grant / Funding (self), Shareholder / Stockholder / Stock options, Officer / Board of Directors: Northern Biologics; Research grant / Funding (self): Mosaic Biomedicals; Research grant / Funding (self): Roche-Glycart. D.D. Von Hoff: Research grant / Funding (institution): Northern Biologics; Advisory / Consultancy, Research grant / Funding (institution): Celgene. L.L. Siu: Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Celgene; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca/MedImmune; Advisory / Consultancy: Morphosys; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy: GeneSeeq; Advisory / Consultancy: Loxo; Advisory / Consultancy: Oncorus; Advisory / Consultancy, Research grant / Funding (institution): Symphogen; Advisory / Consultancy: Seattle Genetics; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (self): GlaxoSmithKine; Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Northern Biologics, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks; Spouse / Financial dependant: Agios. D.M. Hyman: Advisory / Consultancy, Travel / Accommodation / Expenses: Chugai Pharma; Advisory / Consultancy: CytomX Therapeutics; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Bayer Pharmaceuticals; Advisory / Consultancy, Travel / Accommodation / Expenses: Genentech / Roche; Research grant / Funding (self): Loxo Oncology; Research grant / Funding (self): PUMA Biotechnology; Research grant / Funding (self): Bayer Pharmaceuticals; Research grant / Funding (institution): Northern Biologics. J. Tabernero: Advisory / Consultancy: Array Biopharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Beigene; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Chugai; Advisory / Consultancy: Genentech, Inc; Advisory / Consultancy: Genmab, A/S; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Imugene Limited; Advisory / Consultancy: Inflection Biosciences Limite; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Kura Oncology; Advisory / Consultancy: MSD; Advisory / Consultancy: Menarini; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Merrimack; Advisory / Consultancy: Merus; Advisory / Consultancy: Molecular Partners; Advisory / Consultancy: Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen; Research grant / Funding (institution): Northern Biologics, Symphogen A/S, Servier SL, Roche Farma SA, Pharma Mar, Novartis Farmacéutica SA, Amgen, Debiopharm International SA, Janssen-Cilag SA, Mologen AG; Leadership role: ESMO.
Resources from the same session
2507 - KEYLYNK-010: Phase 3 Study of Pembrolizumab (pembro) Plus Olaparib (OLA) vs Enzalutamide (ENZA) or Abiraterone (ABI) in ENZA- or ABI-Pretreated Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Had Progression on Chemotherapy (CTx)
Presenter: Evan Yu
Session: Poster Display session 3
Resources:
Abstract
2944 - PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastasic hormone-sensitive prostate cancer.
Presenter: Jose Arranz Arija
Session: Poster Display session 3
Resources:
Abstract
3535 - A phase 1 study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Ben Tran
Session: Poster Display session 3
Resources:
Abstract
4951 - ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer (EudraCT: 2018-002350-78, NCT03903835)
Presenter: Johan Lindberg
Session: Poster Display session 3
Resources:
Abstract
2892 - A phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
2427 - The Extended/Phase II Study of Safety And Tolerability Of Proxalutamide (GT0918) In Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone (Abi) Or Enzalutamide (Enza)
Presenter: Nicholas Vogelzang
Session: Poster Display session 3
Resources:
Abstract
3224 - Addition of an oral docetaxel treatment (ModraDoc006/r) to androgen deprivation therapy (ADT) and intensity-modulated radiation therapy (IMRT) in patients with high risk N+M0 prostate cancer
Presenter: Marit Vermunt
Session: Poster Display session 3
Resources:
Abstract
3312 - A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen therapy with apalutamide in patients with biochemical progression after radical prostatectomy.
Presenter: Piet Dirix
Session: Poster Display session 3
Resources:
Abstract
2829 - Health-Related Quality of Life (HRQoL) and Updated Follow-Up From KEYNOTE-057: Phase 2 Study of Pembrolizumab (pembro) for Patients (pts) With High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG)
Presenter: Ronald de Wit
Session: Poster Display session 3
Resources:
Abstract
2673 - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract